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40min 60%   
Deyevetal.
2003(20)







1hr 80% Yes 98% 
Chenetal.
2008(14)

















































































































































































































































































































































































































































































































































































































Peptide PeptideSequence ExpectedMW(g/mol) ObtainedMW(g/mol)
1 LAAALEHHHHHH 1408.69 1408.72
2 CKLAAALEHHHHHH 1639.79 1639.31
3 LAAALEHAHAHA 1210.62 1210.58
4 CKLAAALEHAHAHA 1441.72 1441.72
5 LAAALEHHHH 1134.57 1134.59
6 CKLAAALEHHHH 1365.67 1365.42
7 LAAALEHAHA 1139.58 1139.38
8 CKLAAALEHAHA 1370.69 1370.66
9 LAAALEHAAH 1139.58 1139.60





















































































































































































































































































































































































































































































































































































































































































































15 15.5 16 16.5 17 17.5 18 18.5 19 19.5 20 20.5 21
A210
tR/min
15 15.5 16 16.5 17 17.5 18 18.5 19 19.5 20 20.5 21
A210














































































































































































Protein (M) Expected (Da) Found (Da)
LAAALEHHHHHH 705.351 [P + 2H ]2+ 705.348
LAAALEHHHHHH-187/185Re(CO)3
840.317 
[P1 + Re(CO)3 + H]2+
840.307

























































































































































































































L – A – A – A –L-E-H-H-H-H-H-H















































































































































































































































































































































































































































































































































































































































































































































 Spot PeptideSequence pI DLU
A RͲEͲEͲVͲPͲRͲRͲSͲGͲLͲSͲAͲGͲHͲR 11.52 11,418.60
B GͲYͲLͲRͲKͲPͲKͲSͲMͲHͲKͲRͲFͲFͲV 11.17 14,541.60
C EͲKͲKͲTͲKͲIͲRͲSͲLͲHͲNͲKͲLͲLͲN 10.46 8,309.30
D RͲRͲLͲKͲGͲPͲGͲTͲPͲAͲFͲPͲHͲYͲL 11 14,371.40
a YͲVͲAͲSͲNͲRͲRͲSͲIͲFͲFͲRͲTͲSͲH 11.71 5,839.40
b GͲLͲAͲKͲSͲFͲGͲSͲPͲNͲRͲAͲYͲTͲH 9.99 6,769.80
c DͲYͲFͲLͲLͲSͲHͲSͲLͲLͲPͲAͲLͲCͲD 4.51 6,445.90
d HͲVͲQͲRͲVͲMͲRͲTͲPͲGͲCͲQͲSͲPͲG 10.35 6,069.00
e RͲKͲQͲHͲAͲRͲVͲSTͲVͲKͲYͲDͲRͲRͲE 10.93 5,791.90























Spot PeptideSequence pI DLU
A RͲEͲEͲVͲPͲRͲRͲSͲGͲLͲSͲAͲGͲHͲR 11.52 21,160.05
B GͲGͲVͲKͲKͲRͲKͲSͲSͲSͲSͲVͲHͲLͲM 11.26 15,651.70
C GͲYͲLͲRͲKͲPͲKͲSͲMͲHͲKͲRͲFͲFͲV 11.17 13,792.50
D EͲKͲKͲTͲKͲIͲRͲSͲLͲHͲNͲKͲLͲLͲN 10.46 17,746.45
E RͲKͲQͲHͲAͲRͲVͲSTͲVͲKͲYͲDͲRͲRͲE 10.93 13,041.75
a GͲLͲAͲKͲSͲFͲGͲSͲPͲNͲRͲAͲYͲTͲH 9.99 10.449.25
b GͲPͲRͲVͲWͲYͲVͲSͲNͲIͲDͲGͲTͲHͲI 6.74 11,287.50
c PͲAͲLͲKͲRͲSͲHͲSͲDͲSͲLͲDͲHͲDͲI 6.01 10,326.40



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































labelling efficiencies that were greater than those of the sequences in the “Controls”
categorythateithercontainednoHisresiduesornoaminoacids.Noobviousspecifictrends
in labellingefficienciesweredetectedwith regards to thedifferent characteristicsof the
sequences.










Amino AcidsÆ Arg and Lys” category (purple) after 15mins labellingwere significantly
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Figure6Ͳ3.Thecalculated%Bound[188Re(CO)3]
+forallpeptidesequencesafterexposuretohuman
serumfor48hrs.Thedatahasbeenpresentedaccordingtothecategoriespreviouslyestablished
basedonthecharacteristicsofthepeptidesequences.

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 6.5 DISCUSSION&CONCLUSION

Preliminarystudiestoevaluatewhether[188Re(CO)3]
+behavesanalogouslyto[99mTc(CO)3]
+
inlabellingtheHisͲTaggedCelluspotTMarrayhavebeencarriedout.Ithasbeenrevealed
thatHisͲTaggedpeptidesequencescontainingmultiplepositivelychargedaminoacidsalso
demonstratedapreferentialcoordinationto[188Re(CO)3]
+incomparisontoallother
sequencesontheCelluspotTMarray.Itcanbededucedfromthisobservationthatpeptide
sequenceswithahighpI,duetothepresenceofmultipleArgorLysresidues,will
demonstrateefficientlabellingwith[188Re(CO)3]
+.Inaddition,the[188Re(CO)3]Ͳpeptide]
+
conjugateswerestableinhumanserumforupto48hrsandarethereforesuitableforpreͲ
clinicalandclinicalapplications.Consequently,theJWTͲTag,LRRRLAHHHHHH,engineered
attheCͲterminaloftheJ591scFvproteininchapter4,canalsobeusedforlabellingwith
[188Re(CO)3]
+andtheTcandRecomplexesbehavehighlyanalogously.Theoreticallythiswill
provideamethodofdeliveringatherapeuticdoseofɴradiationtothesiteofaction,which
forJ591scFvisprostatecancer.

Itmustbetakenintoconsiderationthattheexperimentwasonlyperformedusingone
CelluspotTMarrayandthelabellingofpeptideswith[188Re(CO)3]
+hasnotbeeninvestigated
insolution.Itisnotpossibletoconcludewhethertheresultsobservedforthepeptideson
solidphasecorrelatewiththe[188Re(CO)3]
+labellingofthepeptidesinsolution.The
[188Re(CO)3]
+radiolabellingofArg/HisͲTaggedpeptidesshouldbecarriedoutinsolution
beforeanydefinitiveconclusionsaremade,althoughitisexpectedthattheanalogywillbe
maintainedasitwasforthe99mTccomplexes.Itwillbeinterestingtofurtherexaminethe
radiolabellingofproteinswith[188Re(CO)3]
+viatheArg/HisͲTagmethodandhencethe
possibleuseofa[188Re(CO)3Ͳprotein]
+conjugateasatherapeuticradiopharmaceutical.





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7. Conclusion&Future



ThepurposeofthisthesiswastoimproveuponthecurrentlyavailablesiteͲspecificprotein
labellingmethodsinanattempttosatisfytherequirementsforanoptimalbiomolecular
conjugateasdiscussedinChapter1.1.Focuswasonthedevelopmentofthe(His)6ͲTagasa
methodofsiteͲspecificlabellingwith[M(CO)3]
+complexes,whereM=99mTcor[Re(CO)3]
+.
ThiswasachievedthroughtheoptimisationofaHisͲTaggedproteogenicaminoacid
sequenceusingthecharacteristicfeaturesoftheaminoacidssurroundingtheHisresidues
toinfluenceitscoordinationto[M(CO)3]
+complexes.

AhighthroughputscreeningmethodologywasestablishedusingCelluspotTMpeptidearrays
thatprovidedanefficientmethodologyfortheanalysisofmultiplepeptidesequencesas
suitabletagsforcoordinationof[M(CO)3]
+.Itprovidedastraightforwardmethodinwhich
labellingconditionssuchaspH,temperatureandbuffercouldalsobeassessed.
RadiolabellingaspecificallydesignedHisͲTaggedpeptidelibrary(HisͲTaggedCelluspotTM
array)with[99mTc(CO)3]
+and[188Re(CO)3]
+wasabletoprovideextensiveinformationwith
regardstowhichcharacteristicsprovidedapositiveornegativeimpactonthelabelling
efficiency.

AsummaryofthemainoutcomespostradiolabellingoftheHisͲTaggedCelluspotTMarray
with[99mTc(CO)3]
+canbeseenbelow:

1. Agoodcorrelationwasobservedbetweentheradiolabellingofthepeptidesin
solutionandonsolidphasewhichconfirmsthesuitabilityandreliabilityoftheHisͲ
TaggedCelluspotTMarray.
2. Multiplepositivelychargedaminoacidssignificantlyimprovedlabellingefficiencyof
theHisͲcontainingsequences.
3. Multiplenegativelychargedaminoacidsweredetrimentaltowardsthelabelling
efficiency.
4. SequenceswithapI>9.5,duetothepresenceofpositivelychargedaminoacids,
demonstratedanimprovedlabellingefficiency.
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5. Aminimumof2Argresiduesor3Lysresiduesarerequiredtogivethemost
efficientlabellingefficiencyandtoprovideasufficientamountofpositivecharge
onthesequencetoyieldapI>9.5.
6. SequencesinwhichArgispositionedseparatingtheHisresiduesisnotafavourable
arrangementintermsoflabellingefficiencye.g.RRRXXHHHHHH>XXXXRHRHRHR
7. LabellingefficiencyincreaseswiththenumberofHisresiduesincludedinthe
sequencee.g.HHHHHH>HHHH>HXHXHX>HXHX>HXXH.
8. Cysdoescontributetowardsimprovingthelabellingefficiencybutitisnotthemost
influentialfactorandinthepresenceofArgresidueitdoesnotmakeasignificant
differencetotheradiochemicalyield.
9. MetcanreplaceCys,toavoiddisulfidebondformation,andtheradiochemical
yieldsofthesequencesarecomparable.
10. NolabellingoccursunlessaHisresidueispresentinthesequence.
11. LabellingatpH7.4inPBSbufferwasconsiderablymorefavourablethanatpH5.5
incitratebufferandatpH8.8or7.4inTrisͲHClbuffer.
12. The[99mTc(CO)3]+conjugatesarestableinPBSbufferandhumanserumforatleast
24hours.
13. The[99mTc(CO)3]+conjugatesarestableina1000ͲfoldexcessmolarsolutionofCys
andHisresiduesfor3hrsconsecutively.
14. CLRRRLAHHHHHHwasidentifiedasthesequencewiththehighestlabelling
efficiencyincomparisontoallothersequencesonthearray.Itdemonstratedan8
foldincreaseinradiochemicalyieldincomparisontothebestHisͲTagged
sequencesoftenusedintheliterature.
15. 188Redemonstratesthesamesequencepreferencesas99mTc.

AnArgcontainingHisͲTaggedsequence,LRRRLAHHHHHH(JWTͲTag),wassuccessfully
engineeredattheCͲterminaloftheJ591scFvproteinandillustratedanumberofnotable
advantagesintermsofitsefficiencyinconjugating[99mTc(CO)3]
+ascomparedto
comparatorswithnonͲArglabellingsequences.LabellingefficiencyfortheJWTTagwasso
highthatgreaterthan95%radiochemicalyieldwasachievedafter1hourlabellingata
proteinconcentrationaslowas7ǍM.OthernonͲArgconatinignsequencesrequireda4fold
increaseinproteinconcentrationbeforea95%radiochemicalyieldwasobtained.Clearly
thesuperioraffinityoftheArg/(His)6ͲTagsequencesfor[
99mTc(CO)3]
+istranslationaltoa
proteincontext.The[99mTc(CO)3ͲJ591scFvJWT]
+proteinwaskineticallystableinhuman
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serumandcantheoreticallybeusedinpreͲclinicalandclinicalapplications.Thiswouldthen
provideamethodofimproving[99mTc(CO)3]
+proteinlabellingtotheextentthatlower
proteinconcentrations,shorterincubationtimesandlowertemperaturescanbeusedto
achievehigherlevelsofradiochemicalyieldsandspecificactivity,withagreaterlikelihood
ofavoidingthenecessityofapostͲlabellingpurificationstep.Theseadvantageshave
significantutilityinclinical,diagnosticandresearchsettings.

Intheshortterm,furtherexperimentationshouldbeperformedusingtheJ591scFvJWT
proteinandotherproteinscontainingsequencesofcomparablelabellingefficacy.
EvaluationoftheArg/(His)6TagasastandardisedlabellingmechanismforsiteͲspecific
chelationof[99mTc(CO)3]
+requiresthoroughinvitroandinvivoanalysistoensurethatthe
highlypositivelychargedregiondoesnotaffectthebioactivityoftheproteintowardsthe
target.ThiscanbeperformedfortheJ591scFvJWTproteinasinvivomodelshavealready
beenestablishedwithPSMApositivetumours.Labellingefficiencywithnegativelycharged
HisͲTaggedsequenceswasnotaspromisinghowevertheseGluandAspcontaining
sequencesshouldalsobeinvestigatedinaproteinlabellingcontext.Inadditionitwillalso
beinterestingtoengineertheJWTtagintootherproteinsequencesandassesstheir
labellingabilitiesandbiologicalfunctionfordifferenttargets.Ultimately,itwouldbe
desirableiftheJWTTagcouldbeincorporatedintolibrariesoftrialrecombinantproteins
forthelargescaleevaluationoftheirsuitabilityasradiopharmaceuticals.

ThereweresomesuggestionspresentedastowhythepositivelychargedHisͲTagged
sequencesdemonstratedahighlabellingefficiencyfor[99mTc(CO)3]
+.Someoftheseinclude:
1. [M(CO)3(H2O)3]+isnegativelychargedduetoligandsubstitutionoftheH2O
moleculesforanionswithinthelabellingsolution.
2. Ahydrogenbondedphosphatebridgecanformbetween[M(CO)3]+andtheArg
residues.
3. TheArgreducesthepkaoftheamidebackbone.
4. ArginadditiontoHisbindstothe[M(CO)3]+core.
Ithasnotbeenpossibletoreachadefinitiveconclusionandfurtheranalysisshouldbe
performedinanattempttoidentifythecoordinationbetweenanArg/(His)6sequenceand
[M(CO)3]
+.IdeallyNMRstructuralanalysisshouldbeperformedinanattempttodiscoverto
whichexactmoleculesdoes[M(CO)3]
+coordinate.Inadditionotherstudiescouldinvolve
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
ESIͲMSandMSMSontheArg/(His)6ͲTagpeptideconjugateortheArg/(His)6ͲTaggedͲ
proteinconjugate.

Finally,perhapsoneofthemostimportantfeaturesofthisthesisisthedevelopmentofa
highthroughputscreeningmethodology.ThesimplicityoftheHisͲTaggedCelluspotTMarray
incombinationwithitsabilitytoanalysemultiplesequencessimultaneously,providesan
excellentplatformfromwhichthecoordinationofotherradioisotopestoaminoacidscan
beinvestigated.[188Re(CO)3]
+,aradioisotopecomplexanalogousto[99mTc(CO)3]
+,
demonstrateanabilitytocoordinatetothepeptidesontheHisͲTaggedCelluspotTMarray.
Fromthelabellingexperimentitwaspossibletoidentifythat[188Re(CO)3]
+hadsimilar
preferencesto[99mTc(CO)3]
+intermsofitscoordinationtopositivelychargedHisͲTagged
sequences.Furtherstudieswith[188Re(CO)3]
+aredesirableas188Reisahighenergybeta
emitterwhichwouldprovideanopportunityfortheuseofaJWTͲTaggedproteinasa
therapeuticoption.

Thereareotherradioisotopesthatcanbeboundeffectivelybysequencesofaminoacids.
Ofthese,theMO3+andMN2+coresareprimeexampleswhereMalsoequals99mTcor
186/188Reandthemetalisina+5oxidationstate.MO3+isparticulareffectiveinthecontext
ofaminoacidsequencescontainingacysteinethiol.Thecoordinatingatomsarebelievedto
becomprisedoftypicallythethiolatesulphurandthreesequentialanionic,deprotonated
amidenitrogensofthepeptidebackbone.(4Ͳ5)Othershavefoundthatbindingof99mTcO3+
topeptidesisenhancedbythepresenceofaseriesofArgresidues.(6)Manyofthe
sequencespresentontheHisͲTaggedCelluspotTMpeptidearraycontainthiolatesulfur
functionalitiesincombinationwithanionicaminoacidsandArgresidues.Labellingthe
sequencesontheHisͲTaggedarraymayidentifyasequencewithgreateraffinitythanhas
previouslybeenobserved.AnotherpossibilityistodesignanewCelluspotTMarraywith
specificspecificationsforradiolabellingwiththeMO3+complex.

Furthermore,withregardstoproteinorpeptidelabelling,LysandCysaretwoaminoacids
thatareoftenutilisedasmethodsofconjugatingchelatorstoaproteinsequenceduetothe
favourablereactivityoftheirsidechains.Forexamplechelatorswithsulfonylchloride,
isocyanate,isothiocyanateoractivatedesterfunctionalityareoftenusedtotargetLys
residueswhereasdisulfideexchange,alkylationandMichaeladditionreactionsaremore
commonfortargetingCysresiduesinaprotein.(7Ͳ8)Problemsassociatedwiththismethod
areoftenrelatedtothelackofsitespecificitywiththechelatorconjugations.(9)TheHisͲ
TaggedCelluspotTMarraycontainsmanysequenceswithLysandCysresiduessurrounded
bydifferentneighbouringaminoacidsandexperimentscanbedesignedtoassessthe
reactivityoftheLysandCyswithintheseenvironments.Incubationofthearraysina
solutioncontainingaradiolabelledchelatorwithafunctionalitysuitablefortargetingLysor
Cysresidues,mayidentifyaLysorCysthatdemonstratesaparticularlyhighreactivity
towardsthechelator.EngineeringaLysorCyswithinthisenvironmentintoaprotein
structuremayfacilitatesiteͲspecificlabelling.

Insummary,theHisͲTagmethodofsiteͲspecificlabellinghasbeenoptimised.Multiple
positivelychargedaminoacidssuchasArgorLysincombinationwitha(His)6ͲTagappears
tobetheoptimallabellingsequencefor[M(CO)3]
+whereM=99mTcor188Re,the[M(CO)3]
+
conjugatedArg/(His)6ͲTagisstableinhumanserumandthelabellingabilityistranslatable
toaproteinlabellingcontext.ThereisnowastrongpossibilitythattheArg/(His)6ͲTag
labellingmethodologycanbeusedforthehighthroughputscreeningofrecombinant
proteinlibrariestoefficientlyassesstheirsuitabilityasamolecularimagingagent.This
wouldsignificantadvancesinmolecularimaging.

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